Objective: The objective of this study was to compare 0.75% and 0.50% hyperbaric bupivacaine in terms of hemodynamic stability in elective cesarean section. Study Design: Randomized Controlled Trial. Place and duration: Department of Anesthesiology, Intensive care and pain management, Combined Military Hospital, Mardan from September 2021 to March 2022. Methodology: Total 104 women were randomly divided into Group-A (0.50% drug concentration) and Group-B (0.75% drug concentration) hyperbaric bupivacaine. Base line systolic blood pressure was noted. Lumber puncture was done in L3/L4 or L4/L5 space. Reading were taken at 1-min, 3-min, 5-min and 30-min. Drop in SBP<20% from baseline was taken as hemodynamic stability. Stability in SBP systolic blood pressure among the two groups A and B were compared. Results: The mean systolic blood pressure of group A was 123.77±8.43 mmHg while in group B it was 123.66±9.14 mmHg. In group A more than 20% decrease in SBP were noted in 42.3% while in group B it was observed in 63.5% patients. Hemodynamic stabilitywas noted in 57.7% patients and 36.5% patient respectively in study group A and B and difference was significant (p=0.031). Conclusions: The Hyperbaric Bupivacaine 0.50% is found superior than 0.75% interms of hemodynamic stability in patients undergoing elective Cesarean Section. Keywords: Hyperbaric Bupivacaine, Hemodynamic Stability, Elective Cesarean Section
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.